Polycystic kidney disease 1 protein (4192-4202)

Polycystic kidney disease 1 protein (4192-4202) is a synthetic peptide fragment derived from the human PKD1 protein, which plays a central role in renal epithelial cell function and the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This peptide corresponds to a specific amino acid sequence within the larger polycystin-1 protein, a transmembrane molecule involved in cell-cell and cell-matrix interactions, mechanosensation, and intracellular signaling cascades. As a defined molecular probe, it provides researchers with a targeted tool for dissecting the structure-function relationships of PKD1, facilitating studies that aim to elucidate the molecular mechanisms underlying cystogenesis, renal morphogenesis, and cellular signaling pathways associated with polycystic kidney disease.

Epitope mapping: The 4192-4202 fragment of polycystin-1 serves as a valuable reagent for epitope mapping studies, enabling the identification of antigenic determinants recognized by antibodies generated against PKD1. By using this peptide in immunoassays such as ELISA or Western blotting, researchers can characterize antibody specificity and affinity, which is essential for the development of reliable immunodetection tools and for advancing the understanding of immune responses targeting polycystin-1 in disease models.

Protein-protein interaction studies: As a segment of the PKD1 protein, this peptide can be utilized in binding assays to investigate direct and indirect interactions with other molecular partners. Its defined sequence makes it suitable for pull-down experiments, surface plasmon resonance (SPR), or isothermal titration calorimetry (ITC), where it can help uncover binding motifs and interaction domains critical for the assembly of signaling complexes involved in renal epithelial function and cyst formation.

Antibody production: The synthetic peptide corresponding to residues 4192-4202 of polycystin-1 can be employed as an immunogen for the generation of sequence-specific polyclonal or monoclonal antibodies. When conjugated to suitable carrier proteins, it elicits an immune response that yields antibodies with high selectivity for the targeted region of PKD1. These antibodies are valuable tools for immunohistochemistry, immunoprecipitation, and other applications requiring precise detection of polycystin-1 in cellular and tissue samples.

Cell signaling research: The peptide fragment can be applied in functional assays to probe the role of the corresponding PKD1 domain in intracellular signaling pathways. By introducing the peptide into cultured renal epithelial cells or model systems, investigators can assess its impact on downstream signaling events, such as calcium flux, cAMP levels, or kinase activation, thereby dissecting the contribution of specific PKD1 regions to cellular homeostasis and disease progression.

Peptide-based assay development: The defined sequence of the 4192-4202 region allows it to serve as a standard or calibrator in quantitative peptide-based assays. Researchers can incorporate the peptide into mass spectrometry workflows, competitive binding assays, or multiplexed immunoassays to quantify PKD1 fragments or to validate assay specificity. This contributes to the development of robust analytical methods for monitoring protein expression, post-translational modifications, or proteolytic processing events relevant to kidney disease research.

1. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients